FDA requests removal of strongest warning against using cholesterol-lowering statins during pregnancy

If your email program has trouble displaying this email, view as a webpage. Drug Safety Communication The U.S. Food and Drug Administration (FDA) is requesting removal of its strongest warning against using cholesterol-lowering statin medicines in pregnant patients.  Despite the change, most patients should stop statins once they learn they are pregnant.  We have conducted a comprehensive review of all available data and are requesting that statin manufacturers make this change to the prescribing information as part of FDA's ongoing effort to update the pregnancy and breastfeeding information for all prescription medicines.  Patients should not breastfeed when taking a statin because the medicine may pass into breast milk and pose a risk to the baby.  Many can stop statins temporarily until breastfeeding ends.  However, patients requiring ongoing statin treatment should not breastfeed and instead use infant formula or other alternatives. Read More

Manage Subscriptions  |  Unsubscribe All  |  Help

This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA